In accordance with its long-term incentive program (“LTIP”) Ambu A/S has allocated performance share units (PSUs) to members of the Executive Board. Reference is made to the company announcement of 29 January 2021 regarding the implementation of the program and the first allocations.
Pursuant to the Market Abuse Regulation article 19, Ambu A/S hereby notifies receipt of information of the following transactions in Ambu’s shares by persons discharging managerial responsibilities in Ambu A/S.
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |||
| a) | Name | Michael Højgaard Abrahamsen | ||
| 2. | Reason for the notification | |||
| a) | Position/status | CFO | ||
| b) | Initial notifica- tion/Amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auc- tion monitor |
|||
| a) | Name | Ambu A/S | ||
| b) | LEI | 5299008W2A69WX355710 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instru- ment
Identification code |
Performance Share Units linked to shares in Ambu A/S
DK0060946788 |
||
| b) | Nature of the transaction | Allocation of Performance Share Units according to Long-Term Incentive Program. | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| DKK 0 | 7,254 PSUs | |||
| d) | Aggregated information
|
N/A
N/A
|
||
| e) | Date of the transaction | 29 January 2021 | ||
| f) | Place of the transaction | Outside a trading venue | ||
Attachment
New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…
Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…
GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…
Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…